By Samuel kyeremateng, Ph.D. AbbVie, North Chicago, IL Small molecule solid dosage drug product with the drug in the crystalline state is typically preferred due its more desirable properties...
Samuel Kyeremateng, Ph.D. is a Principal Research Scientist and Head of the Material Science and Formulation Modeling Group in NCE Formulation Sciences at AbbVie Deutschland GmbH & Co. KG....
By Dr. Bo Wang, Ph.D. Biogen, Cambridge, MA Absolute configuration determination of an active pharmaceutic ingredient (API) is a crucial task in drug development. Tremendous scientific and technical progress...
Bo Wang obtained his bachelor’s degree in Pharmaceutical Engineering at Southeast University in China. He then completed his Ph.D. study in physical organic chemistry at Kansas State University. After...
By Dedong Wu, Ph.D. Advanced Drug Delivery, PharmSci, R&D, AstraZeneca, Boston US dedong.wu@astrazeneca.com It is challenging and laborious to identify a crystallization process to access an optimal drug substance...
Dedong Wu is an associate principal scientist in Advance Drug Delivery at AstraZeneca. He provides expertise in the areas of drug substance form selection, enabling formulation, targeted drug delivery...
Cheng received his BS in Chemistry at Xiamen University in 1984 and subsequently continued his Ph.D study at the Ohio State University from 1985-1990. He single handedly completed the...
By Scott Shultz, Ph.D. Department of Analytical Research and Development, Merck & Co., Inc., Rahway, NJ, USA The role of the crystalline solid phase is often an enabling feature...
Scott Shultz has over 20 years of pharmaceutical development experience at Merck in the process and analytical development areas. Since 2008 Scott has led numerous efforts in the materials...
Haitao Zhang is an Associate Research Fellow in Chemical Development with Sumitomo Pharma America since 2012. In the current role, he is responsible for in developing, and demonstrating commercially...
